RiverVest Venture Management LLC

In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 8, 2024), RiverVest Venture Management LLC reported 4 stock positions worth $8.1 million. Its top holding was Reneo Pharmaceuticals at 51.7% of the portfolio, followed by Spruce Biosciences (SPRB, 28.3%) and Xilio Therapeutics (XLO, 19.1%). Compared with Q4 2023, it sold out of 1 and added to 1. The biggest buy was Vapotherm (shares +1%) and the biggest sale an exit from Allakos (ALLK).

Most Recent 13F
Q3 2024
Location
St. Louis, MO
CIK
0001812549
Portfolio Value
$8.1M (Q1 2024)
SEC Filing
0001104659-24-058588 ↗ filed May 8, 2024

Holdings Value

0$2.0M$4.0M$6.0M$8.0M$10.0M Q1 2024: $8.1M $8.1M Q1 2024 Q2 2024: $6.8M Q2 2024 Q3 2024: $6.8M Q3 2024

Holdings 4 stocks · $8.1M
RENEO PHARMACEUTICALS INC 51.67% 2,534,220 $4.2M No change
SPRB Spruce Biosciences Inc. 28.35% 2,936,281 $2.3M No change
XLO Xilio Therapeutics Inc. 19.12% 1,441,444 $1.6M No change
VAPOTHERM INC 0.86% 52,881 $70K Add +0.6%

Portfolio Sells Q4 2023 → Q1 2024
ALLK Allakos LLC Sold out 0.00% −50.21

Portfolio Buys Q4 2023 → Q1 2024
VAPOTHERM INC Add +0.6% 0.86% +0.66

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 3$6.8MRENEO PHARMACEUTICALS INC, SPRB, XLO
Q2 2024 4$6.8MRENEO PHARMACEUTICALS INC, SPRB, XLO, VAPOTHERM INC
Q1 2024 4$8.1MRENEO PHARMACEUTICALS INC, SPRB, XLO, VAPOTHERM INC